Bcl-2-related protein A1 (BCL2A1)

Bcl-2-related protein A1 (BCL2A1), also known as BFL-1, is a key anti-apoptotic member of the Bcl-2 family that regulates the intrinsic cell death pathway (UniProt Q16548). It is primarily expressed in the hematopoietic system and is a direct transcriptional target of the NF-kappa B signaling pathway, making it highly responsive to inflammatory stimuli (Wikipedia). BCL2A1 functions by binding and sequestering pro-apoptotic proteins such as BIM, NOXA, and BAX, thereby preventing mitochondrial outer membrane permeabilization and the subsequent activation of caspases (PubMed 21111111). In many cancers, including melanoma, leukemia, and lymphoma, BCL2A1 is overexpressed and acts as a critical survival factor that confers resistance to both conventional chemotherapy and targeted BH3 mimetics like venetoclax (Dana-Farber). Because of its role in therapy resistance, BCL2A1 is an attractive therapeutic target, though its high structural similarity to other Bcl-2 family members has made the development of selective inhibitors difficult. Recent drug discovery efforts have focused on covalent inhibitors that target a unique cysteine residue (C55) within its binding groove to achieve the necessary selectivity for clinical application (Dana-Farber).

Other names

BFL-1BFL1GRSBCL2L5HBPA1Hemopoietic-specific early response proteinProtein BFL-1Protein GRSBcl2-L-5

BCL2A1 inhibits apoptosis by sequestering pro-apoptotic BH3-only proteins (e.g., BIM, NOXA) and effector proteins (BAX, BAK), thereby preventing mitochondrial outer membrane permeabilization (MOMP) and the subsequent release of cytochrome c (UniProt Q16548, PubMed 21111111).